California is currently home to 5615 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221
Recruiting
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2025
Locations: City of Hope - Duarte, Duarte, California
Conditions: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
Register for Updates
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955
Recruiting
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2025
Locations: University of California Irvine Medical Center, Irvine, California
Conditions: Acute Respiratory Distress Syndrome, Infections
Register for Updates
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
NCT07055516
Recruiting
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes over a 6 months treatment period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/27/2025
Locations: Investigative site, Los Angeles, California
Conditions: Obesity and Type 2 Diabetes
Register for Updates
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257
Recruiting
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Orange County Research Center, Lake Forest, California
Conditions: Heart Failure
Register for Updates
Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer
NCT06990542
Recruiting
This is a phase II non-blinded randomized controlled trial of image-guided, tumor-focused radiotherapy in patients with intermediate- or high-risk prostate cancer planning to undergo definitive radiotherapy with or without systemic therapy. The image-guided, tumor-focused radiotherapy will be compared to standard, whole-prostate treatment. The investigators hypothesize that tumor-focused radiotherapy reduces the radiation dose to organs close to the prostate, possibly leading to decreased acute... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of California, San Diego, La Jolla, California
Conditions: Prostate Cancer
Register for Updates
Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department
NCT06961058
Recruiting
Main study objective: compare long-term buprenorphine treatment outcomes for patients who start buprenorphine for opioid use disorder (OUD) in the emergency department and are then referred to get outpatient buprenorphine treatment either via telehealth or at an in-person clinic. Researchers will: Compare rates of establishing outpatient OUD treatment, how long patients stay on buprenorphine, and patients' experience with care to determine whether patient experiences and outcomes are better fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: El Centro Regional Medical Center Emergency Department, El Centro, California
Conditions: Opioid Use Disorder
Register for Updates
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358
Recruiting
The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP. * How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment. Researchers will compare bitopertin to a placebo look-alike substance that contains no drug. Partici... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: Marvel Clinical Research, Huntington Beach, California
Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Register for Updates
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
NCT06859970
Recruiting
The purpose of this early feasibility study is to evaluate the safety and feasibility of the device for percutaneous shunting of the interatrial septum and improvement of heart failure related symptoms. The primary goal is to determine if the device is safe to use. The findings from this study may be used to refine the intended patient population, the design of the device, or develop a subsequent randomized study.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
06/27/2025
Locations: Los Robles Health System, Thousand Oaks, California
Conditions: Heart Failure, Heart Failure NYHA Class III, Heart Failure with Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
Register for Updates
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT06848231
Recruiting
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/27/2025
Locations: UCLA Health, Los Angeles, California
Conditions: Multiple System Atrophy
Register for Updates
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
NCT06843590
Recruiting
The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/27/2025
Locations: Alkermes Investigator Site, Los Angeles, California
Conditions: Idiopathic Hypersomnia
Register for Updates
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Valley Clinical Trials, Covina, California
Conditions: Obesity
Register for Updates
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/27/2025
Locations: Alkermes Investigator Site, Los Angeles, California
Conditions: Narcolepsy Type 2
Register for Updates